FDA grants three priority vouchers to psychedelics
The US FDA has granted three Commissioner's National Priority Vouchers to companies working on psychedelics, namely Compass Pathways, Transcend Therapeutics, and the Usona Institute. All three companies have received Breakthrough Therapy Designations from the FDA for their psychedelic-based treatments.
The US FDA has issued three Commissioner's National Priority Vouchers to companies working on psychedelics. The recipients are Compass Pathways, Transcend Therapeutics, and the Usona Institute. Compass Pathways is conducting Phase 3 trials of its synthetic psilocybin COMP360 for treatment-resistant depression. Transcend Therapeutics is developing a methylone-based drug candidate for post-traumatic stress disorder, while the Usona Institute is investigating chemically synthesised psilocybin in patients with major depressive disorder. All three companies have received Breakthrough Therapy Designations from the FDA. The vouchers are expected to accelerate the review process for their treatments.
This content was automatically generated and/or translated by AI. It may contain inaccuracies. Please refer to the original sources for verification.